Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nanocurcumin for the treatment of attention-deficit/hyperactivity disorder
IRCT20090117001556N168Phase 3Recruiting
- Sponsor
- Tehran University of Medical Sciences
- Start
- Feb 2026
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3 trial of nanocurcumin in attention deficit hyperactivity disorder (ADHD), sponsored by Tehran University of Medical Sciences. Started Feb 2026; status: recruiting.
02
Drugs
nanocurcumin
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on IRCT20090117001556N168.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20090117001556N168.